European Nuclear Medicine Guide
1. ICRP. ICRP Publication 53. Radiation dose to patients from radiopharmaceuticals. Annals ICRP 1988;18.
2. ICRP. ICRP Publication 106. Radiation Dose to Patients from Radiopharmaceuticals - Addendum 3 to ICRP Publication 53. Annals ICRP 2008;38.
3. Mattsson S, Johansson L, Leide Svegborn S, Liniecki J, Noßke D, Riklund KÅ, et al. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances. Ann ICRP 2015;44:7–321. https://doi.org/10.1177/0146645314558019.
4. Giovanella L, Treglia G, Iakovou I, Mihailovic J, Verburg FA, Luster M. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2020;47:61–77. https://doi.org/10.1007/s00259-019-04458-6.
5. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1–133. https://doi.org/10.1089/thy.2015.0020.
6. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of Mitochondrial and Plasma Membrane Potentials on Accumulation of Hexakis (2-Methoxyisobutylisonitrile)Technetium(I) in Cultured Mouse Fibroblasts. J NucIMed 1990;31:1646-1653 PMID: 2213187
7. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and Retention of Hexakis (2-Methoxyisobutyl Isonitrile) Technetium(I) in Cultured Chick Myocardial Cells. Mitochondrial and Plasma Membrane Potential Dependence. Circulation. 1990 Nov;82(5):1826-38. doi: 10.1161/01.cir.82.5.1826.PMID: 2225379
8. Del Vecchio S, Salvatore M 99mTc-MIBI in the evaluation of breast cancer biology.Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S88-96. doi: 10.1007/s00259-004-1530-0. Epub 2004 Apr 23.PMID: 15105972 Review
9. Mostafa NM, Elnaggar MS, Abdelhafez YG, Rezk K, Sherif MF, Eltyb HA, Ahmed S, Abu Elnga NE, Hussien MT. In Vivo Detection of Multidrug-Resistance Related Proteins in Locally Advanced Breast Cancer Using 99mTc-MIBI SPECT/CT Imaging: Correlation with Clinical Outcomes. Asian Pac J Cancer Prev. 2024 Sep 1;25(9):3125-3141. doi: 10.31557/APJCP.2024.25.9.3125. PMID: 39342592; PMCID: PMC11700319.
10. Efferth T, Langguth P. Transport processes of radiopharmaceuticals and -modulators. Radiat Oncol. 2011 Jun 6;6:59. doi: 10.1186/1748-717X-6-59. PMID: 21645349; PMCID: PMC3141524.
11. Haimovitz-Friedman A, Yang TJ, Thin TH, Verheij M. Imaging radiotherapy-induced apoptosis. Radiat Res. 2012 Apr;177(4):467-82. doi: 10.1667/rr2576.1. Epub 2012 Feb 21.PMID: 22348249 Review.
12. Campennì A, Ruggeri RM, Siracusa M, Pignata SA, Di Mauro F, Vento A, Trimarchi F, Baldari S. Combined BRAFV600E analysis and 99mTc-MIBI scintigraphy can be a useful diagnostic tool in differentiated thyroid cancer patients with incomplete bio-chemical response to first radioiodine therapy (RAIT): a pilot investigation. J Endocrinol Invest. 2018 Nov;41(11):1283-1288. doi: 10.1007/s40618-018-0864-6. Epub 2018 Mar 16. PMID: 29549631.
13. Erdil TY, Onsel C, Kanmaz B, Caner B, Sonmezoglu K, Ciftci I, Turoglu T, Kabasakal L, Sayman HB, Uslu I Comparison of 99mTc-Methoxyisobutyl Isonitrile and 201T1Scintigraphy in Visualization of Suppressed Thyroid Tissue J Nuc Med 2000; 41:1163-1167. PMID 10914905
14. Erdil TY, Özker K., Kabasakal L , Kanmaz B, Sönmezoglu K, Atasoy KC, Turoglu HT, Uslu I, Isitman AT, Onsel C. Correlation of technetium-99m MIBI and thallium-201 retention in solitary cold thyroid nodules with postoperative histopathology. Eur J Nucl Med 27, 713–720 (2000). https://doi.org/10.1007/s002590050567
15. Giovannella L, Petranovic Ovcaricek P. Functional and molecular thyroid imaging. Q J Nucl Med Mol Imaging 2022 June;66(2):86-92 DOI: 10.23736/S1824-4785.22.03428-8
16. Yordanova A, Mahjoob S, Lingohr P, Kalff J, Türler A, Palmedo H, Biersack HJ, Kristiansen G, Farahati J, Essler M, Ahmadzadehfar H Diagnostic accuracy of [99mTc]Tc-Sestamibi in the assessment of thyroid nodules Oncotarget. 2017 Oct 17;8(55):94681-94691. doi: 10.18632/oncotarget.21866. eCollection 2017 Nov 7.PMID: 29212258
17. Treglia, G.; Caldarella, C.; Saggiorato, E.; Ceriani, L.; Orlandi, F.; Salvatori, M.; Giovanella, L. Diagnostic performance of 99mTc-MIBI scan in predicting the malignancy of thyroid nodules: A meta-analysis. Endocrine 2013 Aug;44(1):70-8. doi: 10.1007/s12020-013-9932-z. Epub 2013 Mar 26.
18. Campennì A, Giovanella L, Siracusa M, Alibrandi A, Pignata SA, Giovinazzo S, Trimarchi F, Ruggeri RM, Baldari S. (99m)Tc-Methoxy-Isobutyl-Isonitrile Scintigraphy Is a Useful Tool for Assessing the Risk of Malignancy in Thyroid Nodules with Indeterminate Fine-Needle Cytology. Thyroid. 2016 Aug;26(8):1101-9. doi: 10.1089/thy.2016.0135. Epub 2016 Jul 8. PMID: 27266385
19. Campennì A, Siracusa M, Ruggeri RM, Laudicella R, Pignata SA, Baldari S, Giovannella L. Differentiating malignant from benign thyroid nodules with indeterminate cytology by 99mTc-MIBIscan: a new quantitative method for improving diagnostic accuracy. Sci Rep 2017 Jul 21;7(1):6147. doi: 10.1038/s41598-017-06603-3.
20. Schenke SA, Campennì A, Tuncel M, Bottoni G, Sager S, Bogovic Crncic T, Rozic D, Görges R, Özcan PP, Groener D, Hautzel H , Klett R, Kreissl MC , Giovanella L Diagnostic Performance of 99mTc-Methoxy-Isobuty-Isonitrile (MIBI) for Risk Stratification of Hypofunctioning Thyroid Nodules: A European Multicenter Study. Diagnostics 2022, 12, 1358. https://doi.org/10.3390/diagnostics12061358.
21. Giovanella L, Avram AM, Iakovou I, Kwak J, Lawson SA, Lulaj E, Luster M, Piccardo A, Schmidt M, Tulchinsky M, Verburg FA, Wolin E. EANM Practice Guideline/SNMMI Procedure Standard for RAIU and Thyroid Scintigraphy. Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2514-2525. doi: 10.1007/s00259-019-04472-8. Epub 2019 Aug 7.PMID: 31392371
22. Avram AM, Giovanella L, Greenspan B, Lawson SA, Luster M, Van Nostrand D, Peacock JG, Petranovic Ovcaricek P, Silberstein E, Tulchinsky M, Verburg FA, Vrachimis A SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version. J Nucl Med 2022 Jun;63(6):15N-35N. PMID: 35649660
23. Mariani G, Tonacchera M, Grosso M, Orsolini F, Vitti P, Strauss HW The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders, Part1: Hyperthyroidism J Nucl Med 2021; 62:304–312 DOI: 10.2967/jnumed.120.243170
24. Schenke SA, Gorges R, Seifert P, Zimny M, Kreissl MC Update on diagnosis and treatment of hyperthyroidism: ultrasonography and functional imaging The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2021 June;65(2):102-12 DOI: 10.23736/S1824-4785.21.03333-1
25. El Mantani Ordoulidis S, Siampanopoulou M. The Role of [99mTc]Tc-Sestamibi in Functional Imaging of the Iodine-Loaded Thyroid Gland J Nucl Med Technol 2023; 51:331–332 DOI: 10.2967/jnmt.123.265665
26. Fischer L, Girotto N, Ilić Tomaš M, Mavrinac M, Lekić A, Antončić D, Bogović Crnčić T. Enhanced Differentiation of Amiodarone-Induced Thyrotoxicosis Types Using Semi-Quantitative 99mTc-MIBI Uptake Analysis: A Pilot Study. Med Sci Monit, 2024; 30: e945444 DOI: 10.12659/MSM.945444
27. Okudan B, Seven B, Gülaldı NCM, Çapraz M, Açıkgöz Y. The Value of 99mTc-MIBI SPECT/CT in the Postoperative Assessment of Patients with Differentiated Thyroid Carcinoma. Curr Med Imaging. 2022;18(4):404-408. doi: 10.2174/1573405617666211108154028. PMID: 34749623.
28. Happel C, Gröner D, Kranert WT, Grünwald F. Evaluation of activity kinetics in breast milk and calculation of the resulting effective radiation dose after 99mTc-MIBI scintigraphy of a breastfeeding women. Nuklearmedizin. 2023 Feb;62(1):45-46. English. doi: 10.1055/a-1937-9466. Epub 2022 Sep 29. PMID: 36174645.
29. Del Vecchio S, Salvatore M. 99mTc-MIBI in the evaluation of breast cancer biology. Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S88-96. doi: 10.1007/s00259-004-1530-0. Epub 2004 Apr 23. PMID: 15105972.
30. Moretti JL, Hauet N, Caglar M, Rebillard O, Burak Z. To use MIBI or not to use MIBI? That is the question when assessing tumour cells. Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):836-42. doi: 10.1007/s00259-005-1840-x. PMID: 15902437.
31. Mostafa NM, Elnaggar MS, Abdelhafez YG, Rezk K, Sherif MF, Eltyb HA, Ahmed S, Abu Elnga NE, Hussien MT. In Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002 Jan;2(1):48-58. doi: 10.1038/nrc706. PMID: 11902585.
32. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 1993 Mar 1;53(5):977-84. PMID: 8094997.
33. O’Doherty MJ, Kettle AG, Wells P, Collins REC, Coakley AJ. Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies. J Nucl Med. 1992;33(3):313–8.
34. Hetrakul N, Civelek AC, Stagg CA, Udelsman R. In vitro accumulation of technetium-99m-sestamibi in human parathyroid mitochondria. Surgery. 2001 Dec;130(6):1011-8. doi: 10.1067/msy.2001.118371. PMID: 11742331.
35. Carpentier A, Jeannotte S, Verreault J, Lefebvre B, Bisson G, Mongeau CJ, Maheux P. Preoperative localization of parathyroid lesions in hyperparathyroidism: relationship between technetium-99m-MIBI uptake and oxyphil cell content. J Nucl Med. 1998 Aug;39(8):1441-4. PMID: 9708524.
36. Pons F, Torregrosa JV, Fuster D. Biological factors influencing parathyroid localization. Nucl Med Commun. 2003 Feb;24(2):121-4. doi: 10.1097/00006231-200302000-00003. PMID: 12548035.
36. Palestro CJ, Tomas MB, Tronco GG. Radionuclide imaging of the parathyroid glands. Semin Nucl Med. 2005 Oct;35(4):266-76. doi: 10.1053/j.semnuclmed.2005.06.001. PMID: 16150247.
37. Petranović Ovčariček P, Giovanella L, Carrió Gasset I, Hindié E, Huellner MW, Luster M, Piccardo A, Weber T, Talbot JN, Verburg FA. The EANM practice guidelines for parathyroid imaging. Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2801-2822. doi: 10.1007/s00259-021-05334-y. Epub 2021 Apr 10. PMID: 33839893; PMCID: PMC8263421.
38. Hindié E, Ugur O, Fuster D, O'Doherty M, Grassetto G, Ureña P, Kettle A, Gulec SA, Pons F, Rubello D; Parathyroid Task Group of the EANM. 2009 EANM parathyroid guidelines. Eur J Nucl Med Mol Imaging. 2009 Jul;36(7):1201-16. doi: 10.1007/s00259-009-1131-z. PMID: 19471928.
39. Krausz Y, Bettman L, Guralnik L, Yosilevsky G, Keidar Z, Bar-Shalom R, Even-Sapir E, Chisin R, Israel O. Technetium-99m-MIBI SPECT/CT in primary hyperparathyroidism. World J Surg. 2006 Jan;30(1):76-83. doi: 10.1007/s00268-005-7849-2. PMID: 16369710.
40. Lavely WC, Goetze S, Friedman KP, Leal JP, Zhang Z, Garret-Mayer E, Dackiw AP, Tufano RP, Zeiger MA, Ziessman HA. Comparison of SPECT/CT, SPECT, and planar imaging with single- and dual-phase (99m)Tc-sestamibi parathyroid scintigraphy. J Nucl Med. 2007 Jul;48(7):1084-9. doi: 10.2967/jnumed.107.040428. Epub 2007 Jun 15. Erratum in: J Nucl Med. 2007 Sep;48(9):1430. PMID: 17574983.
41. Ferlin G, Borsato N, Camerani M, Conte N, Zotti D. New perspectives in localizing enlarged parathyroids by technetium-thallium subtraction scan. J Nucl Med. 1983 May;24(5):438-41. PMID: 6842292.
42. Mansi L, Rambaldi PF, Marino G, Pecori B, Del Vecchio E. Kinetics of Tc-99m sestamibi and Tc-99m tetrofosmin in a case of parathyroid adenoma. Clin Nucl Med. 1996 Sep;21(9):700-3. doi: 10.1097/00003072-199609000-00006.PMID: 8879870
43. Fröberg AC, Valkema R, Bonjer HJ, Krenning EP. 99mTc-tetrofosmin or 99mTc-sestamibi for double-phase parathyroid scintigraphy? Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):193-6. doi: 10.1007/s00259-002-1030-z. Epub 2002 Nov 23. PMID: 12552335.
44. Fjeld JG, Erichsen K, Pfeffer PF, Clausen OP, Rootwelt K. Technetium-99m-tetrofosmin for parathyroid scintigraphy: a comparison with sestamibi. J Nucl Med. 1997 Jun;38(6):831-4. PMID: 9189124.
45. Giordano A, Meduri G. Differences between technetium-99m tetrofosmin and technetium-99m sestamibi in parathyroid scintigraphy. Eur J Nucl Med. 1997 Mar;24(3):347. doi: 10.1007/BF01728776.PMID: 9143476 Clinical Trial.
46. Giovanella L, Avram AM, Iakovou I, Kwak J, Lawson SA, Lulaj E, Luster M, Piccardo A, Schmidt M, Tulchinsky M, Verburg FA, Wolin E. EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy. Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2514-2525. doi: 10.1007/s00259-019-04472-8. Epub 2019 Aug 7. PMID: 31392371.
47. Petranović Ovčariček P, Giovanella L, Hindie E, Huellner MW, Talbot JN, Verburg FA. An essential practice summary of the new EANM guidelines for parathyroid imaging. Q J Nucl Med Mol Imaging. 2022 Jun;66(2):93-103. doi: 10.23736/S1824-4785.22.03427-6. Epub 2022 Feb 15. PMID: 35166093.
48. Mattsson S, Johansson L, Leide Svegborn S, Liniecki J, Noßke D, Riklund KÅ, et al. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances. Ann ICRP 2015;44:7–321. https://doi.org/10.1177/0146645314558019.
49. Hruska CB, Corion C, de Geus-Oei LF, Adrada BE, Fowler AM, Hunt KN, Kappadath SC, Pilkington P, Pereira Arias-Bouda LM, Rauch GM. SNMMI Procedure Standard/EANM Practice Guideline for Molecular Breast Imaging with Dedicated γ-Cameras. J Nucl Med Technol. 2022 Jun 3;50(2):103-110. doi: 10.2967/jnmt.121.264204. PMID: 40168518.
50. Treglia G, Sadeghi R, Schalin-Jäntti C, Caldarella C, Ceriani L, Giovanella L, Eisele DW. Detection rate of (99m) Tc-MIBI single photon emission computed tomography (SPECT)/CT in preoperative planning for patients with primary hyperparathyroidism: A meta-analysis. Head Neck. 2016 Apr;38 Suppl 1:E2159-72. doi: 10.1002/hed.24027. Epub 2015 Jul 6. PMID: 25757222.
51. Ishizuka T, Kajita K, Kamikubo K, Komaki T, Miura K, Nagao S, et al. Phospholipid/Ca2+-dependent protein kinase activity in human parathyroid adenoma. Endocrinol Jpn 1987;34:965–8. https://doi.org/10.1507/endocrj1954.34.965.
52. Costa-Guda J, Tokura T, Roth SI, Arnold A. Mitochondrial DNA mutations in oxyphilic and chief cell parathyroid adenomas. BMC Endocr Disord. 2007 Oct 4;7:8. doi: 10.1186/1472-6823-7-8. PMID: 17916247; PMCID: PMC2099428.
53. Ciappuccini R, Licaj I, Lasne-Cardon A, Babin E, de Raucourt D, Blanchard D, et al. 18F-fluorocholine positron emission tomography/computed tomography is a highly sensitive but poorly specific tool for identifying malignancy in thyroid nodules with indeterminate cytology: the Chocolate study. Thyroid. 2021 May;31(5):800-809. doi: 10.1089/thy.2020.0555. Epub 2020 Dec 23. PMID: 33183159; PMCID: PMC8110014.
54. Jager PL, Vaalburg W, Pruim J, Vries EGE de, Langen K-J, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432–45. PMID 11337520
55. Caldarella C, Treglia G, Isgrò MA, Giordano A. Diagnostic performance of positron emission tomography using 11C-methionine in patients with suspected parathyroid adenoma: a meta-analysis. Endocrine 2013;43:78–83. https://doi.org/10.1007/s12020-012-9746-4.
56. Petranović Ovčariček P, Giovanella L, Carrió Gasset I, Hindié E, Huellner MW, Luster M, et al. The EANM practice guidelines for parathyroid imaging. Eur J Nucl Med Mol Imaging 2021;48:2801-22.
57. Noskovicova L, Balogova S, Aveline C, Tassart M, Zhang-Yin J, Kerrou K, et al 18F-Fluorocholine-positron emission tomography/computerized tomography (FCH PET/CT) imaging for detecting abnormal parathyroid glands: indication, practice, interpretation and diagnostic performance. Semin Nucl Med 2024;54(6):875-895. doi: 10.1053/j.semnuclmed.2024.08.002. Epub 2024 Sep 20. PMID: 39306520.
58. Broos WAM, Wondergem M, Knol RJJ, van der Zant FM. Parathyroid imaging with 18F-fluorocholine PET/CT as a first-line imaging modality in primary hyperparathyroidism: a retrospective cohort study. EJNMMI Res 2019 ;9(1):72. doi: 10.1186/s13550-019-0544-3. PMID: 31367807; PMCID: PMC6669225
59. Seyedinia SS, Mirshahvalad SA, Schweighofer-Zwink G, Hehenwarter L, Rendl G, Pirich C, Beheshti M. Evolving role of [18F]Flurocholine PET/CT in assessing primary hyperparathyroidism: can it be considered the first-line functional imaging approach? J Clin Med. 2023;12(3):812. doi: 10.3390/jcm12030812. PMID: 36769460; PMCID: PMC9917644..
60. Talbot JN, Périé S, Tassart M, Delbot T, Aveline C, Zhang-Yin J, et al. 18F-fluorocholine PET/CT detects parathyroid gland hyperplasia as well as adenoma: 401 PET/CTs in one center. Q J Nucl Med Mol Imaging. 2023 Jun;67(2):96-113. doi: 10.23736/S1824-4785.23.03513-6. Epub 2023 Mar 30. PMID: 36995286.
61. Lezaic L, Rep S, Sever MJ, Kocjan T, Hocevar M, Fettich J. ¹⁸F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. Eur J Nucl Med Mol Imaging 2014.41: 2083-9. Doi: 10.1007/s00259-014-2837-0
62. Michaud L, Burgess A, Huchet V, Lefèvre M, Tassart M, Ohnona J, et al. Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism? J Clin Endocrinol Metab. 2014;99(12):4531-6. doi: 10.1210/jc.2014-2821. PMID: 25215560.
63. Evangelista L, Ravelli I, Magnani F, Iacobone M, Giraudo C, Camozzi V, et al D.. 18F-choline PET/CT and PET/MRI in primary and recurrent hyperparathyroidism: a systematic review of the literature. Ann Nucl Med 2020; 34(9):601-619. doi: 10.1007/s12149-020-01507-1. Epub 2020 Aug 7. PMID: 32767248; PMCID: PMC7438295.
64. Piccardo, A, Bottoni G, Boccalatte LA, Camponovo C, Musumeci M, Bacigalupo L, et al. Head-to-head comparison among 18F-choline PET/CT, 4D contrast-enhanced CT, and 18F-choline PET/4D contrast-enhanced CT in the detection of hyperfunctioning parathyroid glands: a systematic review and meta-analysis. Endocrine. 2021; 74(2):404-412. DOI: 10.1007/s12020-021-02798-8
65. Quak E, Cavarec M, Ciappuccini R, Girault G, Rouzier R, Lequesne J. Detection, resection and cure: a systematic review and meta-analysis of 18F-choline PET in primary hyperparathyroidism. Q J Nucl Med Mol Imaging 2023;67(2):122-129. doi: 10.23736/S1824-4785.23.03512-4. Epub 2023 Feb 9. PMID: 36756935.
66. Orevi M, Freedman N, Mishani E, Bocher M, Jacobson O, Krausz Y. Localization of parathyroid adenoma by 11C-choline PET/CT: preliminary results. Clin Nucl Med 2014;39:1033–8. https://doi.org/10.1097/RLU.0000000000000607.
67. Noltes ME, Kruijff S, Appelman APA, Jansen L, Zandee WT, Links TP, et al. Head-to-head comparison of [11C]methionine PET, [11C]choline PET, and 4-dimensional CT as second-line scans for detection of parathyroid adenomas in primary hyperparathyroidism. Eur J Nucl Med Mol Imaging 2024; 51(4):1050-1059. doi: 10.1007/s00259-023-06488-7. Epub 2023 Nov 17. PMID: 37975887; PMCID: PMC10881780.
68. Kluijfhout WP, Pasternak JD, Drake FT, Beninato T, Gosnell JE, Shen WT, et al. Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. Langenbecks Arch Surg 2016;401:925–35. Doi: 10.1007/s00423-016-1425-0.
69. Bioletto F, Barale M, Parasiliti-Caprino M, Prencipe N, Berton AM, Procopio M, et al. Comparison of the diagnostic accuracy of 18F-Fluorocholine PET and 11C-Methionine PET for parathyroid localization in primary hyperparathyroidism: a systematic review and meta-analysis. Eur J Endocrinol 2021; 185: 109-20.DOI: 10.1530/EJE-21-0038
70. Mathey C, Keyzer C, Blocklet D, Van Simaeys G, Trotta N, Lacroix S, et al. 18F-Fluorocholine PET/CT is more sensitive than 11C-Methionine PET/CT for the localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism. J Nucl Med 2022; 63: 785-91. DOI: 10.2967/jnumed.121.262395
71. Deandreis D, Terroir M, Al Ghuzlan A, Berdelou A, Lacroix L, Bidault F, et al. 18Fluorocholine PET/CT in parathyroid carcinoma: a new tool for disease staging? Eur J Nucl Med Mol Imaging. 2015 ;42(12):1941–2. https://doi.org/10.1007/s00259-015-3130-6.
72. Su C, Zhang J, Yang H, Xu Y, Lu X. Diagnosis and treatment of liver metastases of parathyroid carcinoma. Front Endocrinol (Lausanne). 2022;13:982972. doi: 10.3389/fendo.2022.982972. PMID: 36303876; PMCID: PMC9592764.
73. Boucher A, Delabie J, Lussey-Lepoutre C, Haissaguerre M, Ouvrard E, Lavinia V, et al. Performance of [18F]fluorocholine PET/CT in MEN1-related primary hyperparathyroidism before initial surgery or for persistent/recurrent disease. Eur J Nucl Med Mol Imaging. 2024;51(5):1349-1360. doi: 10.1007/s00259-023-06537-1. Epub 2023 Dec 7. PMID: 38057652.
74. Talbot JN, Zhang-Yin J, Kerrou K, Aveline C, Vagne B, Bélissant O, et al. Multiple endocrine neoplasia type 1 or 4: detection of hyperfunctioning parathyroid glands with 18F-fluorocholine PET/CT. Illustrative cases and pitfalls. Q J Nucl Med Mol Imaging. 2022;66(2):130-140. doi: 10.23736/S1824-4785.22.03440-9. Epub 2022 Jan 10. PMID: 35005879.
75. Xue Y, Li W, Xia Z, Lei C, Cao Y, Wang Z, Pang H. The role of 18F-FCH PET/CT in patients with uremic hyperparathyroidism compared with 99mTc-sestaMIBI SPECT/CT and ultrasonography. EJNMMI Res. 2019;9(1):118. doi: 10.1186/s13550-019-0583-9. PMID: 31879808; PMCID: PMC6933043.
76. Chen YH, Chen HT, Lee MC, Liu SH, Wang LY, Lue KH, Chan SC. Preoperative F-18 fluorocholine PET/CT for the detection of hyperfunctioning parathyroid glands in patients with secondary or tertiary hyperparathyroidism: comparison with Tc-99m sestamibi scan and neck ultrasound. Ann Nucl Med. 2020;34(8):527-537. doi: 10.1007/s12149-020-01479-2. Epub 2020 May 20. PMID: 32436180,
77. Grimaldi S, Young J, Kamenicky P, Hartl D, Terroir M, Leboulleux S, et al. Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT. Eur J Nucl Med Mol Imaging 2018;45:1772–80. https://doi.org/10.1007/s00259-018-4018-z.
78. Talbot JN, Périé S, Tassart M, Safa JB, Montravers F, Balogova S. The presence of an arteria lusoria should be checked when reporting 18 F-FCH PET/CT performed to localize hyperfunctioning parathyroid glands. Clin Nucl Med. 2023;48(11):958-959. doi: 10.1097/RLU.0000000000004814. Epub 2023 Sep 21. PMID: 37756414; PMCID: PMC10581409.
79. Latge A, Riehm S, Vix M, Bani J, Ignat M, Pretet V, et al. 18F-Fluorocholine PET and 4D-CT in patients with persistent and recurrent primary hyperparathyroidism. Diagnostics (Basel). 2021;11(12):2384. doi: 10.3390/diagnostics11122384. PMID: 34943620; PMCID: PMC8700343.
80. Mattsson S, Johansson L, Leide Svegborn S, Liniecki J, Noßke D, Riklund KÅ, et al. Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances. Ann ICRP 2015;44:7–321. https://doi.org/10.1177/0146645314558019.
81. Tolvanen T, Yli-Kerttula T, Ujula T, Autio A, Lehikoinen P, Minn H, et al. Biodistribution and radiation dosimetry of [11C]choline: a comparison between rat and human data. European Journal of Nuclear Medicine and Molecular Imaging 2010;37:874–883. https://doi.org/10.1007/s00259-009-1346-z.
82. Deloar HM, Fujiwara T, Nakamura T, Itoh M, Imai D, Miyake M, et al. Estimation of internal absorbed dose of L-[methyl-11C]methionine using whole-body positron emission tomography. Eur J Nucl Med 1998;25:629–33. https://doi.org/10.1007/s002590050265.
83. Michaud L, Balogova S, Burgess A, Ohnona J, Huchet V, Kerrou K, et al. A pilot comparison of 18F-fluorocholine PET/CT, ultrasonography and 123I/99mTc-sestaMIBI dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism: influence of thyroid anomalies. Medicine (Baltimore) 2015;94:e1701. https://doi.org/10.1097/MD.0000000000001701.
84. Cook GJR, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999;26:1363–78. https://doi.org/10.1007/s002590050597.
85. Yen R-F, Wu V-C, Liu K-L, Cheng M-F, Wu Y-W, Chueh S-C, et al. 131I-6 -Iodomethyl-19-Norcholesterol SPECT/CT for Primary Aldosteronism Patients with Inconclusive Adrenal Venous Sampling and CT Results. Journal of Nuclear Medicine 2009;50:1631–1637. https://doi.org/10.2967/jnumed.109.064873
86. ICRP. ICRP Publication 80. Radiation Dose to Patients from Radiopharmaceuticals: A Compendium of Current Information Related to Frequently Used Substances. Annals ICRP 1998;28.
87. Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2801-2822. doi: 10.1007/s00259-021-05334-y. Epub 2021 Apr 10. The EANM practice guidelines for parathyroid imaging Petra Petranović Ovčariček 1 2, Luca Giovanella 1 3 4, Ignasi Carrió Gasset 5, Elif Hindié 6, Martin W Huellner 7, Markus Luster 1 8, Arnoldo Piccardo 9, Theresia Weber 10, Jean-Noël Talbot 11, Frederik Anton Verburg 12 13